SOUTH SAN FRANCISCO, Calif., May 10 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE) today reported financial results for the first
quarter ended March 31, 2007.
For the first quarter of 2007, the company reported a net loss of $29.4
million, or $0.49 per fully diluted share, compared with net income of $4.0
million, or $0.08 per fully diluted share, for the same period in 2006. The
change from net income to net loss in the current quarter is attributed
primarily to the absence of gains from sales of marketable securities
compared to the first quarter of 2006, at which time the company had a gain
of $62.7 million from the sale of 3.0 million shares of common stock of
Abgenix, its former subsidiary.
Revenues for the first quarter ended March 31, 2007 were $1.3 million
compared with revenues of $0.2 million for the comparable period in 2006.
The difference is due to timing of revenue from existing licensing
arrangements which varies from quarter to quarter.
The company's research and development costs were $24.0 million for the
first quarter of 2007 compared with $25.3 million for the first quarter of
2006. The decrease is primarily due to the timing of expenses related to
the ongoing Phase 3 clinical trials of the company's lead product
development program, GVAX immunotherapy for prostate cancer. General and
administrative expenses were $5.2 million for the first quarter of 2007
compared to $5.0 million for the corresponding period in 2006.
Cell Genesys ended the first quarter of 2007 with approximately $138.6
million in cash, cash equivalents and short-term investments. Following the
end of the quarter, the company raised gross proceeds of $60 million in a
registered direct offering of common stock and warrants and also reached a
favorable settlement with the IRS regarding the audit of the company's 2000
tax return. The settlement with the IRS is for approximately $3.5 million
in taxes and interest and results in a decrease in accrued income tax
liabilities of approximately $21 million.
"We are pleased with our business progress during the first quarter as
well as recent news from our clinical-stage product programs, in particular
an encouraging report of the final survival data from our second Phase 2
trial of GVAX immunotherapy for prostate cancer," stated Stephen A.
Sherwin, M.D., chairman and chief executive officer of Cell Genesys. "We
are also fortunate to continue to have the financial resources we need to
move our clinical programs forward, most importantly the ongoing Phase 3
clinical trials for our lead product, GVAX immunotherapy for prostate
cancer."
First Quarter and Other Recent Highlights:
-- Announced final, updated results from a second multi-center Phase 2
trial of GVAX immunotherapy for prostate cancer which evaluated
escalating doses of the immunotherapy in 80 patients with metastatic
hormone-refractory prostate cancer (HRPC). Additional follow-up of
the 22 patients who received the dose that is comparable to that
being employed in the company's ongoing Phase 3 program indicates
that the median survival is 35.0 months. The company previously
reported final median survival results from its first multi-center
Phase 2 trial of GVAX immunotherapy for prostate cancer in 34
patients with metastatic HRPC that showed an overall median survival
of 26.2 months. The survival results from the two, independent
multi-center Phase 2 clinical trials compare favorably to the
previously published median survival of 18.9 months for metastatic
hormone-refractory prostate cancer patients treated with Taxotere(R)
(docetaxel) chemotherapy plus prednisone, the current standard of
care for these patients.
-- Reported at the American Society of Clinical Oncology (ASCO)
Prostate Cancer Symposium in February 2007, encouraging follow-up
data on the first twelve patients with advanced prostate cancer
treated on a Phase 1 clinical trial of Cell Genesys' GVAX
immunotherapy for prostate cancer, administered in combination with
Medarex's fully human anti-CTLA-4 antibody, ipilimumab (MDX-010).
The twelve patients who have completed treatment to date include six
patients who received the combination therapy at doses currently
being evaluated in both GVAX and ipilimumab Phase 3 clinical trials.
Antitumor activity has been observed in five of these six patients
including prostate-specific antigen (PSA) declines of greater than
50% that were maintained in four of these patients for at least six
months with the longest response ongoing at more than 12 months.
Moreover, clinical evidence of antitumor activity has been observed
in three of these five PSA responders, including improvement of
multiple lesions on bone scan, resolution of abdominal lymph node
disease by CT scan, and improvement in pain due to bone metastases,
respectively.
-- Reported at the ASCO Gastrointestinal Cancer Symposium in January
2007, follow-up data from a Phase 2 clinical trial of GVAX
immunotherapy for pancreatic cancer in 60 patients with operable
pancreatic cancer who received the immunotherapy after surgical
resection of their tumor and adjuvant radiation and chemotherapy.
The updated results showed a median survival of 26.8 months. This
compares favorably with published, historical data from multiple
single-arm and randomized studies in patients undergoing pancreatic
cancer surgery and adjuvant therapy for whom the median survival has
been reported to be in the range of 17 to 22 months, including the
most recently reported results for gemcitabine chemotherapy.
-- Reported at the American Association for Clinical Research meeting
in April 2007, immune response data from two previously conducted
Phase 2 clinical trials of GVAX immunotherapy for prostate cancer.
Evaluation of antibody responses in patients with advanced prostate
cancer from these studies shows that the GVAX cell-based
immunotherapy induces antibody responses to a broad array of
prostate cancer-associated antigens, including some not previously
known to be associated with prostate cancer. In addition, the
antibody responses to this non patient-specific product were
predominantly patient-specific and unique from patient to patient,
indicating the potential advantage of a cell-based multi-antigen
product such as GVAX to generate the broadest and most relevant
immune response.
-- Raised gross proceeds of $60 million in a registered direct offering
of 10.8 million shares of common stock at a price of $5.55 per share
with selected institutional investors. In conjunction with the
offering, the company issued warrants to purchase 2.2 million shares
of common stock at a price of $7.18 per share.
-- Entered into a new Committed Equity Financing Facility with
Kingsbridge Capital Limited in February 2007 pursuant to which
Kingsbridge committed to purchase, subject to certain conditions, up
to $75 million of our common stock. The company had previously
raised $35.0 million in a similar transaction with Kingsbridge.
-- Reached a favorable settlement with the IRS regarding the audit of
the company's 2000 tax return. The settlement with the IRS is for
approximately $3.5 million in taxes and interest and results in a
decrease in accrued income tax liabilities of approximately $21
million in taxes and interest.
Cell Genesys is focused on the development and commercialization of
novel biological therapies for patients with cancer. The company is
currently pursuing two clinical stage product platforms - GVAX(TM) cancer
immunotherapies and oncolytic virus therapies. Ongoing clinical trials
include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2
trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and
a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell
Genesys continues to hold an equity interest in its former subsidiary,
Ceregene, Inc., which is developing gene therapies for neurodegenerative
disorders. Cell Genesys is headquartered in South San Francisco, CA, and
has its principal manufacturing operation in Hayward, CA. For additional
information, please visit the company's website at http://www.cellgenesys.com.
Cell Genesys will host its quarterly conference call to discuss events
that occurred during the first quarter of 2007 at 2:00 p.m. PST on
Thursday, May 10, 2007. Investors may listen to the webcast of the
conference call live on Cell Genesys' website. Alternatively, investors may
listen to a replay of the call by dialing 800-475-6701 from locations in
the U.S. and 320-365-3844 from outside the U.S. The call-in replay will be
available for at least 72 hours following the call. Please refer to
reservation number 872186.
Statements made herein about the company, other than statements of
historical fact, including statements about the company's progress, results
and timing of clinical trials and preclinical programs and the nature of
product pipelines are forward-looking statements and are subject to a
number of uncertainties that could cause actual results to differ
materially from the statements made, including risks associated with the
success of clinical trials and research and development programs, the
regulatory approval process for clinical trials, competitive technologies
and products, patents, continuation of corporate partnerships and the need
for additional financings. For information about these and other risks
which may affect Cell Genesys, please see the company's Annual Report on
Form 10-K for the year ended December 31, 2006 filed on March 1, 2007 as
well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed
from time to time with the Securities and Exchange Commission. The company
assumes no obligation to update the forward-looking information in this
press release.
Contact: Ina Cu, Investor Relations, +1-650-266-3200.
-- FINANCIAL CHARTS TO FOLLOW --
SELECTED CONSOLIDATED FINANCIAL INFORMATION
CONSOLIDATED STATEMENTS OF OPERATIONS DATA
(unaudited, in thousands, except per share data)
Three months ended
March 31,
2007 2006
Revenue $1,273 $176
Operating expenses:
Research and development 24,015 25,314
General and administrative 5,245 5,028
Total operating expenses 29,260 30,342
Loss from operations (27,987) (30,166)
Other income (expense):
Gain on sale of Abgenix, Inc. common stock - 62,677
Interest and other income 1,922 1,560
Interest expense (2,599) (2,622)
Income (loss) before income taxes (28,664) 31,449
Income tax provision (785) (27,435)
Net income (loss) $(29,449) $4,014
Basic net income (loss) per common share $(0.49) $0.09
Diluted net income (loss) per common share $(0.49) $0.08
Weighted average shares of common
stock outstanding - basic 60,649 45,619
Weighted average shares of common
stock outstanding - diluted 60,649 61,930
CONSOLIDATED BALANCE SHEET DATA
(in thousands) March 31, December 31,
2007 2006
(unaudited) Note 1
Cash, cash equivalents and short-term
investments, including restricted cash $138,554 $154,074
Prepaid expenses and other current assets 2,571 3,481
Property and equipment, net 126,558 129,643
Unamortized debt issuance costs
and other assets 3,843 3,969
Total assets $271,526 $291,167
Other current liabilities $14,610 $15,904
Current portion of accrued income taxes 21,025 35,410
Other liabilities 3,012 2,851
Non-current portion of accrued income taxes 11,702 -
Non-current portion of capital
lease obligation 48,047 48,475
Convertible senior notes 145,000 145,000
Stockholders' equity 28,130 43,527
Total liabilities and
stockholders' equity $271,526 $291,167
Note 1. Derived from audited
financial statements.
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com/
CONTACT:
Ina Cu, Investor Relations, +1-650-266-3200
|
